Literature DB >> 7906205

Inhibitory effects of 2-O-octadecylascorbic acid and other vitamin C and E derivatives on the induction of enzyme-altered putative preneoplastic lesions in the livers of rats fed a choline-deficient, L-amino acid-defined diet.

Y Mizumoto1, D Nakae, H Yoshiji, N Andoh, K Horiguchi, T Endoh, E Kobayashi, T Tsujiuchi, N Shimoji, A Denda.   

Abstract

Effects of a lipophilic derivative of vitamin C, 2-O-octadecylascorbic acid (CV-3611), as well as its parent L-ascorbic acid (AscA), DL-alpha-tocopherol (alpha-T) and its hydrophilic derivative, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), on the number and size of gamma-glutamyltransferase (GGT)-positive putative preneoplastic lesions were examined and compared with their influences on 8-hydroxyguanine formation in DNA and 2-thiobarbituric acid-reacting substance generation in the livers of rats fed a choline-deficient, L-amino acid-defined (CDAA) diet for 12 weeks. A total of 90 male Fischer 344 rats, 6 weeks old, were divided into 18 groups each consisting of five rats. Group 1 received the CDAA diet alone; Groups 2, 3 and 4 received the CDAA diet containing respectively 0.01, 0.05 and 0.10% CV-3611; Groups 5-7, 8-10 and 11-13 similarly received the CDAA diet containing AscA, alpha-T and Trolox, respectively, at these same low, middle and high concentrations; Group 14 received a choline-supplemented, L-amino acid-defined (CSAA) diet alone; Groups 15-18 were given the CSAA diet containing CV-3611, AscA, alpha-T and Trolox, respectively, all at the 0.10% level. While all four vitamin derivatives exerted inhibitory effects on all four parameters, in each case dose-dependently, CV-3611 demonstrated the most pronounced effects. The present results indicated that lipophilic vitamin C derivatives may be particularly effective chemopreventive agents against CDAA diet-associated, oxidative stress-related hepatocarcinogenesis via its superior antioxidative properties.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906205     DOI: 10.1093/carcin/15.2.241

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  In situ detection, by spin trapping, of hydroxyl radical markers produced from ionizing radiation in the tumor of a living mouse.

Authors:  H J Halpern; C Yu; E Barth; M Peric; G M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

2.  Inhibition by green tea extract of diethylnitrosamine-initiated but not choline-deficient, L-amino acid-defined diet-associated development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in rat liver.

Authors:  K Tamura; D Nakae; K Horiguchi; H Akai; Y Kobayashi; H Satoh; T Tsujiuchi; A Denda; Y Konishi
Journal:  Jpn J Cancer Res       Date:  1997-04

Review 3.  Ascorbate Is a Primary Antioxidant in Mammals.

Authors:  Junichi Fujii; Tsukasa Osaki; Tomoki Bo
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

4.  Different roles of 8-hydroxyguanine formation and 2-thiobarbituric acid-reacting substance generation in the early phase of liver carcinogenesis induced by a choline-deficient, L-amino acid-defined diet in rats.

Authors:  D Nakae; Y Mizumoto; H Yoshiji; N Andoh; K Horiguchi; K Shiraiwa; E Kobayashi; T Endoh; N Shimoji; K Tamura
Journal:  Jpn J Cancer Res       Date:  1994-05

5.  Inhibition of early-phase exogenous and endogenous liver carcinogenesis in transgenic rats harboring a rat glutathione S-transferase placental form gene.

Authors:  D Nakae; A Denda; Y Kobayashi; H Akai; H Kishida; T Tsujiuchi; Y Konishi; T Suzuki; M Muramatsu
Journal:  Jpn J Cancer Res       Date:  1998-11

6.  Prevention by methionine of enhancement of hepatocarcinogenesis by coadministration of a choline-deficient L-amino acid-defined diet and ethionine in rats.

Authors:  T Tsujiuchi; E Kobayashi; D Nakae; Y Mizumoto; N Andoh; H Kitada; K Ohashi; T Fukuda; A Kido; M Tsutsumi
Journal:  Jpn J Cancer Res       Date:  1995-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.